北京大学学报(医学版) ›› 2024, Vol. 56 ›› Issue (1): 51-56. doi: 10.19723/j.issn.1671-167X.2024.01.009

• 论著 • 上一篇    下一篇

双层软组织缝合封闭技术在下颌骨中早期药物相关性颌骨骨坏死患者手术治疗中的应用

周颖,赵宁,黄竑远,李庆祥,郭传瑸,郭玉兴*()   

  1. 北京大学口腔医学院·口腔医院口腔颌面外科,国家口腔医学中心,国家口腔疾病临床医学研究中心,口腔生物材料和数字诊疗装备国家工程研究中心,口腔数字医学北京市重点实验室,国家卫生健康委员会口腔医学计算机应用工程技术研究中心,国家药品监督管理局口腔生物材料重点实验室,北京 100081
  • 收稿日期:2023-10-08 出版日期:2024-02-18 发布日期:2024-02-06
  • 通讯作者: 郭玉兴 E-mail:gladiater1984@163.com
  • 基金资助:
    北京大学口腔医院国家临床重点专科建设项目(PKUSSNKP-202114);中国博士后自然基金(2022M720289);中华口腔医学会临床研究基金(CSA-SIS2022-0);北京市自然科学基金(7212137);国家口腔医学中心适宜技术推广项目(2023NCSHTP03)

Application of double-layer soft tissue suture closure technique in the surgical treatment of patients with mandible medication-related osteonecrosis of the jaw of early and medium stages

Ying ZHOU,Ning ZHAO,Hongyuan HUANG,Qingxiang LI,Chuanbin GUO,Yuxing GUO*()   

  1. Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology & National Center of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Biomaterials and Digital Medical Devices & Beijing Key Laboratory of Digital Stomatology & NHC Research Center of Engineering and Technology for Computerized Dentistry & NMPA Key Laboratory for Dental Materials, Beijing 100081, China
  • Received:2023-10-08 Online:2024-02-18 Published:2024-02-06
  • Contact: Yuxing GUO E-mail:gladiater1984@163.com
  • Supported by:
    the National Clinical Key Discipline Construction Project(PKUSSNKP-202114);China Postdoctoral Science Foundation(2022M720289);Chinese Stomatological Association Clinical Research Fund(CSA-SIS2022-0);Beijing Municipal Natural Science Foundation(7212137);the National Stomatology Center Suitable Technology Promotion Project(2023NCSHTP03)

RICH HTML

  

摘要:

目的: 探究双层软组织缝合封闭技术在单纯应用抗骨吸收药物引起的发生在下颌骨的中早期药物相关性颌骨骨坏死(medication-related osteonecrosis of the jaw, MRONJ)患者手术治疗中的临床应用效果。方法: 选择2021年10月至2022年9月于北京大学口腔医院四病区经手术治疗的中早期下颌骨MRONJ患者的病历资料进行回顾性分析,收集患者术前基线临床资料,包括原发疾病、伴发疾病、用药方案(药物种类、用药时长)、MRONJ分期、临床症状、影像学表现等,所有患者在手术中行下颌骨边缘切除术去除坏死骨,运用双层软组织缝合封闭技术关闭伤口,术后定期复查随访,评价双层软组织缝合封闭技术的治疗效果及并发症,并对患者进行疼痛评分和功能状态评价。结果: 研究共纳入13例患者(女12例,男1例),年龄(66.69±13.14)岁。原发疾病包括骨质疏松7例,肺癌2例,乳腺癌3例,前列腺癌1例;2例伴发糖尿病,2例伴发心血管疾病,1例伴发干燥综合征。9例患者静脉注射唑来膦酸,平均用药时间(37.7±20.0)个月,7例患者同时服用了来曲唑片等其他药物;3例患者应用地舒单抗注射液,平均用药时间(10.3±11.9)个月;5例患者服用阿仑膦酸钠片,平均用药时间(55.20±27.20)个月,2例患者不同程度地服用醋酸泼尼松片或阿卡波糖片。MRONJ 1期4例,2期9例。13例患者均采用双层软组织缝合封闭技术关闭伤口,术后平均随访11.9个月(9~17个月),13例患者皆治愈,无溢脓等并发症发生。患者术前Karnofsky功能状态评分量表(Karnofsky performance status, KPS)评分为(68.46±14.05)分,术后评分为(82.31±15.36)分,差异有统计学意义(P < 0.05)。患者术前疼痛评估视觉模拟评分量表(visual analogue scale,VAS)评分为(5.77±0.73)分,术后评分为(0.38±0.51)分,差异有统计学意义(P < 0.001)。结论: 双层软组织缝合封闭技术在中早期单纯使用抗骨吸收类药物的下颌骨MRONJ患者中可以取得良好的临床治疗效果,可为用药情况更加复杂的MRONJ患者提供临床治疗思路。

关键词: 药物相关性颌骨骨坏死, 双层软组织缝合封闭技术, 边缘性颌骨切除, 抗骨吸收药物, 外科治疗

Abstract:

Objective: To investigate the clinical application effect of double-layer soft tissue (DLST) suture closure technique in patients with mandible medication-related osteonecrosis of the jaw (MRONJ) of early and medium stages resulted in application of anti-bone-resorptive drugs. Methods: Early to medium stage mandible MRONJ patients who underwent surgical treatment in the fourth ward of Peking University School and Hospital of Stomatology from October 2021 to September 2022 were included. Clinical information of the patients were collected, including primary disease, concomitant disease, medication regimen (drug type, duration of medication), MRONJ stage, clinical symptoms, imaging manifestations, etc. During surgery, after using marginal mandibulae resection to remove the necrotic bone, the wound was closed using DLST closure technique. Regular post-operative follow-up was performed to evaluate the therapeutic effect and complications of the DLST technique, the pain score and functional status of the patiens were evaluated. Results: This study totally included 13 patients, 12 women and 1 man, aged (66.69±13.14) years. Seven patients had osteoporosis, 2 had lung cancer, 3 had breast cancer and 1 had prostate cancer among their primary diseases; 7 had no concomitant diseases, 2 had diabetes mellitus, 2 had cardiovascular disease and 1 had dry syndrome. Intravenous zoledronic acid were used in 9 patients, the average duration was (37.7±20.0) months, and other drugs, such as letrozole tablets were taken in 7 patients at the same time; Denosumab injection was used in 3 patients for an average of (10.3±11.9) months; Alendronate sodium tablets were taken in 5 patients for an average of (55.20±27.20) months, and prednisone acetate tablets or acarbose tablets were taken to varying degrees in 2 patients. The average post-operative follow-up was 11.9 months (9 to 17 months), and all the 13 patients were cured without complications, such as pus overflow and so forth. The pre-operative score of Karnofsky performance status (KPS) in the patients was 68.46±14.05, and the post-operative score was 82.31±15.36, and the difference was statistically significant (P < 0.05). The pre-operative score of visual analogue scale (VAS) in the patients was 5.77±0.73 and the post-operative score was 0.38±0.51, and the difference had statistical significance (P < 0.001). Conclusion: The double-layer soft tissue suture closure technique can achieve good clinical results in patients with MRONJ of the mandible using anti-bone-resorptive drugs alone, and can provide clinical treatment ideas for MRONJ patients with more complicated drug use.

Key words: Medication-related osteonecrosis of the jaw, Double-layer soft tissue suture closure technique, Marginal mandibulectomy, Anti-bone-resorptive drugs, Surgical treatment

中图分类号: 

  • R782

图1

双层软组织缝合封闭设计示意图(下颌骨)"

图2

患者双层软组织缝合封闭术手术过程"

表1

患者的基线临床资料"

Case Gender Age/years Primary disease Concomitant disease Chemotherapeutics Stage of MRONJ Clinical manifestation Imaging manifestation
Anti-bone resorption drugs/months Else
1 Female 63 Lung cancer - Zoledronic acid/26, denosumab/2 Crizotinib capsule 2 Soft tissue fistula Local thickening of bone
2 Male 71 Prostatic cancer - Zoledronic acid/31 Flutamide tablets, leuprorelin acetate, microspheres for injection 2 Soft tissue fistula Diffuse sclerosis of bone
3 Female 40 Breast cancer - Zoledronic acid/30, pamidronate/28 Palbociclib, fulvestrant, everolimus tablets 2 Soft tissue fistula Local thickening of bone
4 Female 64 Osteoporosis - Alendronate sodium/48, zoledronic acid/1 - 1 Soft tissue fistula Sequestration
5 Female 79 Osteoporosis - Zoledronic acid/60 - 1 Soft tissue fistula Sequestration,diffuse sclerosis of bone
6 Female 87 Osteoporosis Diabetes Alendronate sodium/103 Acarbose tablets 1 Soft tissue fistula Sequestration,diffuse sclerosis of bone
7 Female 85 Osteoporosis - Alendronate sodium/41 - 1 Soft tissue fistula Diffuse sclerosis of bone
8 Female 63 Lung cancer - Zoledronic acid/57 - 2 Soft tissue fistula Sequestration,diffuse sclerosis of bone
9 Female 63 Breast cancer Diabetes Zoledronic acid/64, denosumab/5 Trastuzumab, pertuzumab, paclitaxel, fulvestrant, capecitabine tablets 2 Soft tissue fistula Diffuse sclerosis of bone
10 Female 70 Osteoporosis Hypertension Zoledronic acid/40, alendronate sodium/48 - 1 Soft tissue fistula Sequestration
11 Female 74 Osteoporosis Coronary heart disease Denosumab/24 Leiflunomide tablets, tripterygium glycosides tablets, 1 Bone exposure Sequestration,diffuse sclerosis of bone
12 Female 52 Breast cancer - Zoledronic acid/30 Letrozole tablets, fulvestran, abemaciclib 2 Soft tissue fistula Uneven alveolar bone density
13 Female 56 Osteoporosis Sicca syndrome Alendronate sodium/36 Prednisone acetate tablets 1 Soft tissue fistula Sequestration,diffuse sclerosis of bone

图3

病例4(A)和病例9(B)术后6个月复查口腔内软组织伤口愈合"

图4

病例6术前(A)和术后(B)6个月曲面断层X线片"

1 Marx RE . Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic[J]. J Oral Maxillofac Surg, 2003, 61 (9): 1115- 1117.
doi: 10.1016/S0278-2391(03)00720-1
2 Ruggiero SL , Dodson TB . American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw: 2014 update[J]. J Oral Maxillofac Surg, 2014, 72 (10): 1938- 1956.
doi: 10.1016/j.joms.2014.04.031
3 郭玉兴, 王佃灿, 王洋, 等. 二膦酸盐药物治疗乳腺癌骨转移发生颌骨坏死的临床特点[J]. 北京大学学报(医学版), 2016, 48 (1): 80- 83.
doi: 10.3969/j.issn.1671-167X.2016.01.014
4 Ruggiero SL , Dodson TB , Aghaloo T , et al. American association of oral and maxillofacial surgeons' position paper on medication-related osteonecrosis of the jaws: 2022 update[J]. J Oral Maxillofac Surg, 2022, 80 (5): 920- 943.
doi: 10.1016/j.joms.2022.02.008
5 Yarom N , Shapiro CL , Peterson DE , et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline[J]. J Clin Oncol, 2019, 37 (25): 2270- 2290.
doi: 10.1200/JCO.19.01186
6 Carlson ER . Management of antiresorptive osteonecrosis of the jaws with primary surgical resection[J]. J Oral Maxillofac Surg, 2014, 72 (4): 655- 657.
doi: 10.1016/j.joms.2013.12.007
7 Abu-ld MH , Warnke PH , Gottschalk J , et al. "Bis-phossy jaws"-high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw[J]. J Craniomaxillofac Surg, 2008, 36 (2): 95- 103.
doi: 10.1016/j.jcms.2007.06.008
8 Wilde F , Heufelder M , Winter K , et al. The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2011, 111 (2): 153- 163.
doi: 10.1016/j.tripleo.2010.04.015
9 Hayashida S , Soutome S , Yanamoto S , et al. Evaluation of the treatment strategies for medication-related osteonecrosis of the jaws (MRONJ) and the factors affecting treatment outcome: A multicenter retrospective study with propensity score matching analysis[J]. J Bone Miner Res, 2017, 32 (10): 2022- 2029.
doi: 10.1002/jbmr.3191
10 Williamson RA . Surgical management of bisphosphonate induced osteonecrosis of the jaws[J]. Int J Oral Maxillofac Surg, 2010, 39 (3): 251- 255.
doi: 10.1016/j.ijom.2009.11.014
11 Lopes RN , Rabelo GD , Rocha AC , et al. Surgical therapy for bisphosphonate-related osteonecrosis of the jaw: Six-year experience of a single institution[J]. J Oral Maxillofac Surg, 2015, 73 (7): 1288- 1295.
doi: 10.1016/j.joms.2015.01.008
12 何悦, 陈珩, 安金刚, 等. 药物相关性颌骨坏死临床诊疗专家共识[J]. 中国口腔颌面外科杂志, 2023, 21 (4): 313- 325.
13 Altay MA , Radu A , Pack SE , et al. Medication-related osteonecrosis of the jaw: An institution' s experience[J]. Cranio, 2020, 38 (5): 333- 341.
doi: 10.1080/08869634.2018.1528711
14 安金刚, 吕晓鸣, 贾宽宽, 等. 下颌下腺转位在下颌骨3期药物相关性颌骨坏死手术中的应用[J]. 中华口腔医学杂志, 2021, 56 (5): 441- 446.
doi: 10.3760/cma.j.cn112144-20210203-00058
15 Caldroney S , Ghazali N , Dyalram D , et al. Surgical resection and vascularized bone reconstruction in advanced stage medication-related osteonecrosis of the jaw[J]. Int J Oral Maxillofac Surg, 2017, 46 (7): 871- 876.
doi: 10.1016/j.ijom.2017.01.023
16 Klingelhöffer C , Zeman F , Meier J , et al. Evaluation of surgical outcome and influencing risk factors in patients with medication-related osteonecrosis of the jaws[J]. J Craniomaxillofac Surg, 2016, 44 (10): 1694- 1699.
doi: 10.1016/j.jcms.2016.08.001
17 Mücke T , Koerdt S , Jung M , et al. The role of mylohyoid flap in the treatment of bisphosphonate-related osteonecrosis of the jaws[J]. J Craniomaxillofac Surg, 2016, 44 (4): 369- 373.
doi: 10.1016/j.jcms.2015.12.017
18 Lemound J , Muecke T , Zeller AN , et al. Nasolabial flap improves healing in medication-related osteonecrosis of the jaw[J]. J Oral Maxillofac Surg, 2018, 76 (4): 877- 885.
doi: 10.1016/j.joms.2017.09.021
[1] 杨榕,李庆祥,毛驰,彭歆,王洋,郭玉兴,郭传瑸. 多模态影像融合技术与颅底-颞下区肿瘤的诊断和治疗[J]. 北京大学学报(医学版), 2019, 51(1): 53-58.
[2] 孙宇, 刘忠军, 党耕町. 颈椎病外科治疗的回顾[J]. 北京大学学报(医学版), 2002, 34(5): 627-629.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!